Teva Copaxone sales fall 12%; NICE says no to new Revlimid use; Valeant cuts forecast;

@FiercePharma: ICYMI: Novartis reports high Bexsero uptake as it pushes ahead in open market. FierceVaccines story | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton

@EricPFierce: Run-ins with the FDA continue to chew up the earnings at India's Ranbaxy. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's full issue of FiercePharmaMarketing. Report | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) reported that Q2 revenue was up 2% to $5 billion but sales of its key product Copaxone were off 12%. Release

> Teva ($TEVA) shareholders approved all the board members up for reappointment over objections by activist shareholder Benny Landa. Story

> U.K. cost watchdog, the National Institute for Health and Clinical Excellence (NICE) is not recommending use of Celgene's ($CELG) Revlimid for treatment of multiple myeloma following one prior treatment with Johnson & Johnson's ($JNJ) Velcade. Story

> Pain drug specialist Endo International raised its forecast after its Q2 profit came in higher than expected. Story

> Valeant Pharmaceuticals ($VRX), which is pursuing a hostile takeover of Allergan ($AGN), has cut its 2014 earnings forecast. Story

Medical Device News

@FierceMedDev: Editor's Corner from @HollmerMark: In Q2, diagnostics venture investment showed some signs of life. Article | Follow @FierceMedDev

@StacyALawrence: Edwards stock surges on strong sales, profits due to legal settlement. Article | Follow @StacyALawrence

@VarunSaxena2: Johnson & Johnson to call for voluntary return of morcellators. WSJ story | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a nanoparticle "alarm clock" to awaken immune systems put to sleep by cancer. Release | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific wins first vaginal mesh case to go to trial. Article | Follow @EmilyWFierce

> FDA advisory panel to consider PMA of TissuGlu surgical adhesive. Article

> Ablatherm ultrasound prostate cancer treatment rebuffed by FDA panel. More

> Fat freezer Zeltiq turns a surprise profit and climbs almost 30%. Story

Biotech News

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: Love this stuff--Sanofi, Regeneron seize a regulatory shortcut in blockbuster PCSK9 race with Amgen. Story | Follow @JohnCFierce

@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. Story via Yahoo! Finance | Follow @DamianFierce

@EmilyMFierce: Merck aims to boost HPV vaccination rates amid lagging numbers. Story | Follow @EmilyMFierce

> Cold Genesys rakes in $13.6M for its cancer-fighting virus. News

> AstraZeneca dials up its immuno-oncology focus with blockbuster hopes. Article

> Gene therapy biotech Avalanche banks $102M in an up-sized IPO. Story

Vaccines News

> Kenya study reveals new malaria vaccine targets. More

> Flu season should return Sanofi to double-digit vaccines growth, CEO says. Item

> Novartis reports high Bexsero uptake as it pushes ahead in open market. Story

> Merck aims to boost HPV vaccination rates amid lagging numbers. Article

> Pfizer finally lands vaccines bulk-up with $635M Baxter buy. News

Pharma Manufacturing News

> Pfizer buys a portion of a vaccine plant from Baxter, J&J sells a vax facility to PaxVax. Item

> Hospira's Rocky Mount plant meets FDA goals, but one in India does not. Article

> Ranbaxy rings up another loss as regulatory problems chew away profits. Story

> Spectacular warehouse burglary left extensive collateral damage for Eli Lilly. Article

> Manufacturing takes it on the chin in Amgen cuts. More

And Finally... Statins, widely prescribed to lower blood cholesterol, may also help wounds heal after surgery, a new study says. Story (sub. req.)

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.